Current Edition


New Models of Innovation in Laboratory Operations

The pandemic laid bare inefficiencies and vulnerabilities across laboratory operations where global supply chain issues, alongside high testing volumes, and the demand for faster turn-around-times …

Continue Reading →

Upstream Bio, a richly funded startup, reveals its lead drug and research plans

An inflammatory disease drug cast aside by Astellas Pharma has a new owner in Upstream Bio, an emerging biotechnology startup led by industry veteran Samantha …

Continue Reading →

Agios to cut jobs as it moves away from exploratory research

Dive Brief: Agios Pharmaceuticals, a developer of rare disease treatments, revealed on Monday plans to eliminate up to 50 jobs involved in exploratory research, part …

Continue Reading →

Undeterred by gene therapy’s struggles, a startup launches into a downturn

Gene therapy companies have been especially vulnerable to a public market downturn that’s shaken the biotech sector. But the difficult environment hasn’t stopped venture firms …

Continue Reading →

Cancer Research UK reveals innovation engine underpinned by £400m portfolio of cutting-edge discovery science

Cancer Research UK, the world’s largest independent funder of cancer research, today (Tuesday 26th), unveiled Cancer Research Horizons, its new and ambitious approach to driving …

Continue Reading →

AACR 2022: NK cell promise, more TIGIT questions and extending CAR-T’s reach

Each year, the American Association for Cancer Research’s conference spotlights promising early research into new approaches for attacking tumors. This year’s meeting, held in person …

Continue Reading →

Pfizer buys a private biotech and its RSV drug research

Dive Brief: Pfizer said Thursday it will spend as much as $525 million to buy the privately held biotech ReViral, adding experimental treatments for respiratory …

Continue Reading →

Orchard turns to layoffs in cutting gene therapy research

Dive Brief: Orchard Therapeutics, a London- and Boston-based developer of gene therapies, plans to lay off 30% of its workforce, or about 65 employees, as …

Continue Reading →

Gene editing startup Metagenomi raises $175M to advance research pipeline

Metagenomi, a biotech startup that three months ago struck a research alliance with Moderna, has raised $175 million to expand and build on its early …

Continue Reading →

Pfizer, marking fast research pace, starts key trial of RSV vaccine

A vaccine against RSV has proven elusive despite decades of attempts. Pfizer is moving at a surprisingly quick pace to catch up to rivals led …

Continue Reading →

How to Bring Your Oncolytic Virus Innovation to Market: the Secret to Successful Development

Cancer continues to be a major burden on healthcare systems across the world, with global spending on therapies and supportive care drugs expected to reach …

Continue Reading →

CRISPR-Cas9 Knockout Screening Using Primary Human Cells in Drug Discovery

While significant progress has been made carrying out CRISPR screens in immortalised cell lines, a more physiological and clinically relevant alternative is human primary cells, …

Continue Reading →
CAR-T cells

Are We Nearly There Yet? The Ongoing Journey of CAR-T Cell Therapies

CAR-T cells have a genetically engineered T-cell receptor (TCR) that directs their binding to cancer cells. In first-generation CARs, the TCR was engineered to express …

Continue Reading →

Qiagen to expand biomarker research in UK

The new health innovation campus will support the continued growth of businesses which are driving the future shape of medicine and health care. Qiagen has …

Continue Reading →


The Human Vaccines Project, a nonprofit public-private partnership focused on decoding the immune system to improve human health, and Seqirus, a global leader in the …

Continue Reading →

The International Society for Stem Cell Research brings researchers together in Melbourne

The conference is the world’s largest stem cell meeting and will attract more than 2,500 delegates from 60 countries, delivering around $13 million in economic …

Continue Reading →

ExpreS2ion’s U.S. partner Integrated BioTherapeutics launches first ExpreS2-based research product

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) has initiated sales and marketing of its first ExpreS2-based product. The …

Continue Reading →